Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Status:
Terminated
Trial end date:
2020-04-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the
disability of patients suffering from progressive multiple sclerosis and especially those
with gait impairment.